

REGENERON PHARMACEUTICALS INC

Form 8-K

November 03, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 3, 2011 (November 3, 2011)

REGENERON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

New York	000-19034	13-3444607
(State or other jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices, including zip code)

(914) 347-7000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On November 3, 2011, Sanofi provided updated information regarding ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. A Biologics License Application for marketing approval for ZALTRAP® in previously treated metastatic colorectal cancer was delivered to the U.S. Food and Drug Administration in October of 2011. The filing of a regulatory application for marketing approval in the European Union is expected in the fourth quarter of 2011. ZALTRAP® is being developed in a worldwide collaboration by Regeneron and Sanofi.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2011

REGENERON PHARMACEUTICALS, INC.

By: */s/ Joseph J. LaRosa*
Name: Joseph J. LaRosa
Title: Senior Vice President, General Counsel and
Secretary
